Now on

Rare Partners presents a poster on Thalassemia project

Rare Partners presents a poster on Thalassemia project.

RP announcement - read more
US Patent Office has issued a patent covering the use of trimethylangelicin in Cystic Fibrosis

The United States Patent and Trademark Office has issued on March 15th the US Patent number 9283206 covering the use of trimethylangelicin (TMA) as CFTR Corrector in Bronchial Epithelial Cells.

Press release - read more
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.

Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Run4Usher, #runandimagetofly with us for Usher Syndrome.

Event - read more
Orphan Drug Designation to Sirolimus

The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major

Press release - read more
Agreement between Rare Partners and Fondazione Telethon

Agreement between Rare Partners and Fondazione Telethon 

Press release - read more